People: PharmAthene Inc (PIP)

Summary

Name	Age	Since	Current Position
Mitchel Sayare	64	2011	Independent Chairman of the Board
Eric Richman	52	2010	President, Chief Executive Officer, Director
Linda Chang	46	2011	Chief Financial Officer, Senior Vice President
Jordan Karp	45	2008	Senior Vice President, General Counsel, Corporate Secretary
Francesca Cook	47	2010	Senior Vice President - Policy and Government Affairs
Wayne Morges	65	2010	Senior Vice President - Regulatory Affairs and Quality
Elliott Elliott		2012	Chief Scientific Officer
John Gill	60	2007	Independent Director
Brian Markison	53	2011	Independent Director
Joel McCleary	63	2007	Independent Director
Jeffrey Runge	56	2009	Independent Director
Derace Schaffer	64	2007	Independent Director
Steven St. Peter	45	2007	Independent Director
Stacey Jurchison			Director - Corporate Communications

» Insider Trading

Biographies

Name	Description
Mitchel Sayare	Dr. Mitchel Sayare, Ph.D., serves as an Independent Chairman of the Board of PharmAthene Inc., Dr. Sayare has been a member of the Board since April 2010 and replaced John Pappajohn (who retired as director) as Chairman of the Board in July 2011. Until 2010, Dr. Sayare served as the Chairman of the Board of public company ImmunoGen, Inc. (a position he had held since 1989). In addition, he served as ImmunoGen’s Chief Executive Officer from 1986 to December 31, 2008, and as its President from 1986 to 1992, and from 1994 to July 2008. Prior to joining ImmunoGen, he served as Vice President of Development of Xenogen from 1982 to 1985. Prior to that he was Assistant Professor of Biophysics and Biochemistry at the University of Connecticut. Dr. Sayare holds a Ph.D. in Biochemistry from Temple University School of Medicine.
Eric Richman	Mr. Eric I. Richman serves as President, Chief Executive Officer, Director of PharmAthene Inc., Mr. Richman was appointed President and Chief Operating Officer on March 25, 2010, interim Chief Executive Officer on May 2, 2010 and Chief Executive Officer on October 20, 2010. He became a Director of PharmAthene on May 17, 2010. Prior to his March 25, 2010 appointment, Mr. Richman was Senior Vice President, Business Development and Strategic Planning since the merger on August 3, 2007, and from August 2003 through August 3, 2007 held the same position with Former PharmAthene. Prior to joining the Company, Mr. Richman held various commercial and strategic positions of increasing responsibility over a 12 year period at MedImmune, Inc. from its inception and was Director, International Commercialization at that company. Mr. Richman served as Director of Lev Pharmaceuticals and currently serves as Director of ADMA Biologics, Inc. and American Bank. Mr. Richman received a Bachelor of Science in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a Master of Business Administration from the American Graduate School of International Management.
Linda Chang	Ms. Linda L. Chang serves as Chief Financial Officer, Senior Vice President of PharmAthene Inc., since November 7, 2011. Ms. Chang had been employed for the last 11 years at Human Genome Sciences, Inc., most recently as Senior Director of Finance. Prior to serving at Human Genome Sciences, Ms. Chang was an Associate at Booz Allen & Hamilton. Earlier in her career, Ms. Chang worked at Grant Thornton, LLP and Otsuka America Pharmaceuticals, Inc. Ms. Chang is a Certified Public Accountant. She earned an MBA as well as a Master of Accountancy degree from the University of Georgia and a BS from the University of California, Riverside.
Jordan Karp	Mr. Jordan P. Karp, Esq., serves as Senior Vice President, General Counsel, Corporate Secretary of PharmAthene Inc. Mr. Karp has been Senior Vice President and General Counsel since June 2008 and in January 2012 assumed responsibility for corporate development function. In September 2008, he was appointed corporate secretary. Prior to joining the Company, Mr. Karp was employed by Constellation Energy Group, Inc., a diversified energy company, from October 2001 to November 2007. Mr. Karp served as Vice President & General Counsel for one of Constellation Energy’s operating divisions, Constellation NewEnergy, Inc., a retail marketer of electricity and natural gas, from October 2002 until November 2007. From November 2007 until Mr. Karp joined the Company, he worked as an attorney in private practice. Prior to joining Constellation Energy, Mr. Karp held in-house legal positions of increasing responsibility at MCI Communications Corp. (telecommunications), Guilford Pharmaceuticals Inc. (biopharmaceuticals), and Mentor Technologies Group, Inc. (training and consulting), where Mr. Karp served as Vice President, General Counsel & Corporate Secretary from November 1999 through June 2001. Mr. Karp holds a B.A. in Natural Sciences from The Johns Hopkins University and a J.D. from Yale Law School.
Francesca Cook	Ms. Francesca M. Cook serves as Senior Vice President - Policy and Government Affairs of PharmAthene Inc., since March 2010. In February 2012, She took over responsibility for program management function. Prior to that, she served as Vice President, Policy and Government Affairs since the merger on August 3, 2007 and from October 2003 through August 3, 2007 held the same position with Former PharmAthene. Prior to that, Ms. Cook served as Vice President, Policy & Reimbursement Services for Guilford Pharmaceuticals, Inc. from March 2001 through October 2003 and Vice President at Covance Health Economics and Outcomes Services, a health care consulting firm, from 1996 through 2001. Additionally, Ms. Cook worked in the U.S. Senate and the U.S. Department of Health and Human Services from 1988 through 1993. Ms. Cook received a Bachelor of Arts degree in Biology from Mount Holyoke College and a Master of Public Health degree from Yale University School of Medicine, Department of Public Health.
Wayne Morges	Dr. Wayne Morges, Ph.D., serves as Senior Vice President - Regulatory Affairs and Quality of PharmAthene Inc., From January 2005 through August 3, 2007 held the same position with Former PharmAthene. Prior to that, Dr. Morges was the Vice President of Global Regulatory Affairs, Vaccines for Baxter Healthcare Corporation from June 2000 to November 2004. Previously, Dr. Morges worked at Merck holding various positions of increasing responsibility in Merck’s vaccine division, including heading Quality & Regulatory Affairs for licensed biologicals. Dr. Morges holds a Ph.D. in Microbiology and Immunology from Hahnemann University and Bachelor of Science and Master of Science degrees from Penn State University.
Elliott Elliott	Dr. Arthur Y. Elliott, Ph.D., is appointed as the Chief Scientific Officer of PharmAthene, Inc. Dr. Elliott has served as a scientific advisor to the Company since June 2011. From 2010 to 2011, Dr. Elliott served as Branch Chief, responsible for the U.S. Government’s Anthrax Vaccine Portfolio within the Chemical, Biological, Radiological and Nuclear (CBRN) division of the Biomedical Advanced Research and Development Authority (BARDA). Between 2006 and 2010, Dr. Elliott led, for the Department of Health and Human Services, the Avian Influenza Pandemic Preparedness Program, a government/industry collaboration between three pharmaceutical companies and four government agencies (the Department of Health and Human Services, National Institutes of Health, Centers for Disease Control, and Food and Drug Administration) to accelerate the production and stockpiling of Pandemic Influenza Vaccine for the United States Strategic National Stockpile. Prior to his government service, from 2000 to 2006, Dr. Elliot served as an on-site consultant to Aventis (Sanofi Pasteur) Pharmaceutical Corporation, advising on the design and implementation of new manufacturing facilities for the production of influenza vaccine. From 1994 to 1999, Dr. Elliott served as Chief Operating Officer and Senior Vice President, and starting in 1998 Acting President, at North American Vaccine, Inc. Prior thereto, Dr. Elliott served for 16 years with Merck & Co., Inc., ultimately as Executive Director, Biological Operations, Merck Manufacturing Division. From 1970 to 1978, Dr. Elliott served as an associate professor in the departments of urologic surgery and microbiology at the University of Minnesota. Dr. Elliott is a named author on approximately 50 scientific publications. Dr. Elliott earned his Ph.D. in virology from Purdue University, and an M.S. in microbiology and a B.A. in biology, both fom North Texas State University.
John Gill	Mr. John Gill serves as an Independent Director of PharmAthene Inc., since August 3, 2007. From February 2004 to August 3, 2007 served as a member of the Board of Directors and as Chairman of the Audit Committee of predecessor, privately-held PharmAthene (“Former PharmAthene”). Mr. Gill is currently the President, Chief Executive Officer and a Director of TetraLogic Pharmaceuticals Corporation, a private biopharmaceutical company, and has served in these positions since 2003. He is also an advisor or director of other private companies, the Kimmel Cancer Center at Thomas Jefferson University, and other non-profit community organizations. Mr. Gill has previously held positions at 3-Dimensional Pharmaceuticals and SmithKline Beecham. Mr. Gill received a Bachelor of Arts degree from Rutgers University.
Brian Markison	Mr. Brian A. Markison serves as an Independent Director of PharmAthene Inc., since September 22, 2011. He is President and Chief Executive Officer, and member of the Board, of Fougera Pharmaceuticals, Inc. Mr. Markison has more than 30 years of experience in the pharmaceutical industry. He formerly served as Chairman (from May 2007 through February 2011) and President and Chief Executive Officer (from July 2004 through February 2011) of King Pharmaceuticals, which he joined as Chief Operating Officer before being promoted to President and Chief Executive Officer and elected Chairman. Prior to King Pharmaceuticals, Mr. Markison held various senior leadership positions at Bristol-Myers Squibb, including President of Oncology/Virology and Oncology Therapeutics Network; President, Neuroscience / Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity. Mr. Markison serves on the Board of Directors of public companies Immunomedics, Inc. and Rosetta Genomics, Ltd., where he also serves as Board Chairman. He also serves on the Board of Directors for the Komen Foundation for South / Central New Jersey and on the Board of Trustees for the Pennington School. Mr. Markison received a B.S. degree from Iona College.
Joel McCleary	Mr. Joel W. McCleary serves as an Independent Director of PharmAthene Inc., since August 3, 2007 and from inception to August 3, 2007 was Chairman of the Board of Former PharmAthene. Mr. McCleary is founding member of Four Seasons Ventures LLC founded in 2005. Mr. McCleary is the founder and chairman of Q Global International, an organization which provides close protection services for global leaders against the threat of assassination or incapacitation from chemical, biological and radiological threats. Prior to 2005, Mr. McCleary has served as a White House Aide, Treasurer of the Democratic Party, President of the Sawyer-Miller Group International, and President of the Institute for Asian Democracy. He has served as a consultant to the Department of State. He is a co-founder and former board member of Raydiance Inc. Mr. McCleary received a Bachelor of Arts degree from Harvard University.
Jeffrey Runge	Dr. Jeffrey W. Runge, M.D., serves as an Independent Director of PharmAthene Inc., since December 2009. Dr. Runge is a Principal at The Chertoff Group, a firm providing advisory services in business risk management, homeland security and homeland defense. He is also the President and founder of Biologue, Inc., which provides consulting in biodefense, medical preparedness and injury prevention and control. From 2001 through August of 2008, Dr. Runge served in the Bush administration, first as the head of the National Highway Traffic Safety Administration, and, beginning in September 2005, as the Department of Homeland Security’s (DHS) first Chief Medical Officer. Dr. Runge founded the DHS Office of Health Affairs in 2007 and was confirmed by the Senate as DHS’ first Assistant Secretary for Health Affairs in December of 2007. Dr. Runge also served as Acting DHS Undersecretary for Science and Technology from February through August 2006. In his role at DHS, Dr. Runge oversaw the operations of the department’s biodefense activities, medical preparedness and workforce health protection, including managing DHS’ role in Project BioShield, working with the various federal departments on medical countermeasure assurance. Prior to joining DHS, Dr. Runge was Assistant Chairman of the Department of Emergency Medicine at the Carolinas Medical Center in Charlotte, NC, from 1984 through 2001. Dr. Runge earned his medical degree from the Medical University of South Carolina and his undergraduate degree from the University of the South.
Derace Schaffer	Dr. Derace Lan Schaffer, M.D., serves as an Independent Director of PharmAthene Inc., since August 3, 2007. Dr. Schaffer previously served as Vice Chairman and Chief Executive Officer of Former PharmAthene from April 2005 to August 3, 2007. Dr. Schaffer is the founder and Chief Executive Officer of The Lan Group, a venture capital firm specializing in healthcare and high technology investments. He has served as Chairman of several healthcare companies, including Radiologix, Inc. when it was private, and he has been an active investor for approximately twenty years on a variety of healthcare companies. Dr. Schaffer served as Chief Executive Officer and Chairman of the Board of Ide Imaging Group, P.C. from 1980 to 2001. Dr. Schaffer has served as a director on many healthcare boards of directors, including several health systems and more than ten healthcare services and technology companies. Dr. Schaffer received his postgraduate radiology training at Harvard Medical School and Massachusetts General Hospital, where he served as Chief Resident. He also serves as a director of American CareSource Holdings, Inc. and has previously served as director of King Pharmaceuticals, Inc. and of Allion Healthcare, Inc. (each a public company). Dr. Schaffer is a member of Alpha Omega Alpha, the national medical honor society.
Steven St. Peter	Dr. Steven St. Peter, M.D., serves as an Independent Director of PharmAthene Inc., since August 3, 2007. From October 2004 to August 3, 2007 was a member of the Board of Former PharmAthene. Dr. Steven St. Peter joined MPM Capital in 2004, and he is a Managing Director based in the Boston office. His investment scope includes both venture and buyout transactions across the pharmaceuticals and medical technology industries. He has previous investment experience from Apax Partners and The Carlyle Group. Dr. St. Peter was previously an assistant Clinical Professor of Medicine at Columbia University. He completed his Doctor of Medicine at Washington University and his residency and fellowship at the Hospital of the University of Pennsylvania. Prior to his medical training, he was an investment banker at Merrill Lynch. He also holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas. He is on the Board of the New England Venture Capital Association and is also a director of Aratana Therapeutics, Inc., EKR Therapeutics, Inc., Proteon Therapeutics, Inc., Rhythm Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc. and Xanodyne Pharmaceuticals, Inc.
Stacey Jurchison

Basic Compensation

Name	Fiscal Year Total
Mitchel Sayare	--
Eric Richman	884,872
Linda Chang	--
Jordan Karp	525,098
Francesca Cook	--
Wayne Morges	496,430
Elliott Elliott	--
John Gill	--
Brian Markison	--
Joel McCleary	--
Jeffrey Runge	--
Derace Schaffer	--
Steven St. Peter	--
Stacey Jurchison	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Mitchel Sayare	0	0
Eric Richman	0	0
Linda Chang	0	0
Jordan Karp	0	0
Francesca Cook	0	0
Wayne Morges	0	0
Elliott Elliott	0	0
John Gill	0	0
Brian Markison	0	0
Joel McCleary	0	0
Jeffrey Runge	0	0
Derace Schaffer	0	0
Steven St. Peter	0	0
Stacey Jurchison	0	0

Insider Trading

Name	Shares Traded	Price
RICHMAN ERIC I	22,500	$0.00
COOK FRANCESCA M	3,059	$1.30
KARP JORDAN P	7,863	$1.27
RUNGE JEFFREY W	20,000	$1.30
RICHMAN ERIC I	75,000	$0.00
FUERST THOMAS R	5,000	$1.27
CHANG LINDA L	10,000	$1.38
FUERST THOMAS R	5,000	$1.51
KARP JORDAN P	10,000	$1.51
RICHMAN ERIC I	4,500	$1.50
RICHMAN ERIC I	3,000	$1.50
FUERST THOMAS R	5,000	$1.51
RICHMAN ERIC I	2,500	$1.51
RICHMAN ERIC I	25,000	$0.00
KARP JORDAN P	25,000	$0.00
SCHAFFER DERACE LAN	16,800	$0.70
SCHAFFER DERACE LAN	20,902	$0.70
SAYARE MITCHEL	5,000	$2.17
RUNGE JEFFREY W	17,850	$2.69
RIDDLE VALERIE D	5,354	$4.01
RIDDLE VALERIE D	3,438	$2.46
RIDDLE VALERIE D	3,438	$4.00
RIDDLE VALERIE D	4,775	$2.96
RIDDLE VALERIE D	4,775	$3.75
PAPPAJOHN JOHN	50,000	$3.68

» Full list on Insider Trading

People: PharmAthene Inc (PIP)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: